years of age with severe infection
• Primary outcome of time to clinical improvement
•  N = 20 ruxolitinib + standard care
•  N = 21 placebo + standard care • Ruxolitinib 5 mg twice daily
• Placebo vitamin C 100 mg twice daily • No difference in primary endpoint HR 1.669 (95% CI 0.836–3.335)
• Improvement in lung computerized tomography (CT) scans
• Significantl